Kiersten V. Summers

Array ( [id] => 12908995 [patent_doc_number] => 20180194840 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-12 [patent_title] => COVALENT DIABODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/911869 [patent_app_country] => US [patent_app_date] => 2018-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 74121 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -123 [patent_words_short_claim] => 7 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15911869 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13413277 [patent_doc_number] => 20180258181 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-13 [patent_title] => ANTI-MESOTHELIN ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/911748 [patent_app_country] => US [patent_app_date] => 2018-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14862 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15911748 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13968327 [patent_doc_number] => 10213497 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-02-26 [patent_title] => Vaccine [patent_app_type] => utility [patent_app_number] => 15/910988 [patent_app_country] => US [patent_app_date] => 2018-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 39 [patent_no_of_words] => 41828 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15910988 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14019035 [patent_doc_number] => 20190071511 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-07 [patent_title] => IMMUNOGLOBULIN VARIANTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/905406 [patent_app_country] => US [patent_app_date] => 2018-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34448 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15905406 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13314273 [patent_doc_number] => 20180208673 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-26 [patent_title] => USES OF MONOCLONAL ANTIBODY 8H9 [patent_app_type] => utility [patent_app_number] => 15/899801 [patent_app_country] => US [patent_app_date] => 2018-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52392 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15899801 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16925313 [patent_doc_number] => 11046775 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-29 [patent_title] => CD70 binding molecules and methods of use thereof [patent_app_type] => utility [patent_app_number] => 15/896619 [patent_app_country] => US [patent_app_date] => 2018-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 57 [patent_no_of_words] => 38166 [patent_no_of_claims] => 50 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15896619 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13549079 [patent_doc_number] => 20180326087 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-15 [patent_title] => CD19 BINDING AGENTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/897063 [patent_app_country] => US [patent_app_date] => 2018-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54269 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15897063 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13300247 [patent_doc_number] => 20180201660 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-19 [patent_title] => ANTI-ANGIOGENIC VEGF-AX ISOFORM [patent_app_type] => utility [patent_app_number] => 15/889727 [patent_app_country] => US [patent_app_date] => 2018-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15285 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15889727 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13371965 [patent_doc_number] => 20180237523 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-23 [patent_title] => HUMAN CD3 BINDING ANTIBODY [patent_app_type] => utility [patent_app_number] => 15/888757 [patent_app_country] => US [patent_app_date] => 2018-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19270 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15888757 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13386461 [patent_doc_number] => 20180244772 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-30 [patent_title] => FUSION PROTEINS OF HUMAN PROTEIN FRAGMENTS TO CREATE ORDERLY MULTIMERIZED IMMUNOGLOBULIN FC COMPOSITIONS WITH ENHANCED COMPLEMENT BINDING [patent_app_type] => utility [patent_app_number] => 15/878509 [patent_app_country] => US [patent_app_date] => 2018-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39583 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15878509 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12710953 [patent_doc_number] => 20180128817 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-10 [patent_title] => PREDICTIVE BIOMARKERS FOR CTLA-4 BLOCKADE THERAPY AND FOR PD-1 BLOCKADE THERAPY [patent_app_type] => utility [patent_app_number] => 15/864276 [patent_app_country] => US [patent_app_date] => 2018-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25549 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 146 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15864276 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13461713 [patent_doc_number] => 20180282399 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-04 [patent_title] => TRIVALENT, BISPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 15/857473 [patent_app_country] => US [patent_app_date] => 2017-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14142 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15857473 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12862372 [patent_doc_number] => 20180179298 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-28 [patent_title] => METHOD FOR CONTROLLING AFFINITY OF ANTIBODY FOR ANTIGEN, ANTIBODY WHOSE AFFINITY FOR ANTIGEN HAS BEEN ALTERED, AND ITS PRODUCTION METHOD [patent_app_type] => utility [patent_app_number] => 15/855508 [patent_app_country] => US [patent_app_date] => 2017-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13755 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15855508 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12710950 [patent_doc_number] => 20180128816 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-10 [patent_title] => Reagents and Methods for Cancer Treatment and Prevention [patent_app_type] => utility [patent_app_number] => 15/852606 [patent_app_country] => US [patent_app_date] => 2017-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9022 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15852606 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12644934 [patent_doc_number] => 20180106809 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-19 [patent_title] => ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR [patent_app_type] => utility [patent_app_number] => 15/849962 [patent_app_country] => US [patent_app_date] => 2017-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67545 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -218 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15849962 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12680941 [patent_doc_number] => 20180118813 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-03 [patent_title] => METHOD FOR IMPROVING ANTIBODY [patent_app_type] => utility [patent_app_number] => 15/837569 [patent_app_country] => US [patent_app_date] => 2017-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9320 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15837569 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12770032 [patent_doc_number] => 20180148512 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-31 [patent_title] => FUSION PROTEINS THAT FACILITATE CANCER CELL DESTRUCTION [patent_app_type] => utility [patent_app_number] => 15/830923 [patent_app_country] => US [patent_app_date] => 2017-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15127 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15830923 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12837559 [patent_doc_number] => 20180171026 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-21 [patent_title] => MONOCLONAL ANTIBODY WHICH SPECIFICALLY RECOGNIZES B CELL LYMPHOMA AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 15/829048 [patent_app_country] => US [patent_app_date] => 2017-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12607 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15829048 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15768831 [patent_doc_number] => 20200115433 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-16 [patent_title] => High-Affinity TCR For NY-ESO [patent_app_type] => utility [patent_app_number] => 16/464780 [patent_app_country] => US [patent_app_date] => 2017-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21410 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16464780 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17421542 [patent_doc_number] => 11254987 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-22 [patent_title] => PD-L1 promoter methylation in cancer [patent_app_type] => utility [patent_app_number] => 15/821407 [patent_app_country] => US [patent_app_date] => 2017-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 31 [patent_no_of_words] => 37754 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 170 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15821407 [rel_patent_id] =>[rel_patent_doc_number] =>)